Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Paul Hudson
CEOPaul Hudson
Employees
84,587
Employees84,587
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
84,587
Employees84,587

SNY Key Statistics

Market cap
123.81B
Market cap123.81B
Price-Earnings ratio
12.35
Price-Earnings ratio12.35
Dividend yield
3.22%
Dividend yield3.22%
Average volume
2.13M
Average volume2.13M
High today
$50.75
High today$50.75
Low today
$49.91
Low today$49.91
Open price
$50.00
Open price$50.00
Volume
1.71M
Volume1.71M
52 Week high
$60.12
52 Week high$60.12
52 Week low
$44.62
52 Week low$44.62

Stock Snapshot

As of today, Sanofi(SNY) shares are valued at $50.75. The company's market cap stands at 123.81B, with a P/E ratio of 12.35 and a dividend yield of 3.2%.

As of 2025-11-10, Sanofi(SNY) stock has fluctuated between $49.91 and $50.75. The current price stands at $50.75, placing the stock +1.7% above today's low and 0.0% off the high.

The Sanofi(SNY)'s current trading volume is 1.71M, compared to an average daily volume of 2.13M.

In the last year, Sanofi(SNY) shares hit a 52-week high of $60.12 and a 52-week low of $44.62.

In the last year, Sanofi(SNY) shares hit a 52-week high of $60.12 and a 52-week low of $44.62.

SNY News

Simply Wall St 18h
Assessing Novavax Valuation Following Q3 Revenue Beat and Expanded Sanofi Collaboration

Novavax (NVAX) made headlines this week after reporting Q3 revenue that surpassed expectations, finalizing the transfer of U.S. marketing rights for its COVID-1...

Assessing Novavax Valuation Following Q3 Revenue Beat and Expanded Sanofi Collaboration
Simply Wall St 2d
Novavax Is Down 11.4% After Sanofi Vaccine Deal and Q3 Results - Has the Narrative Shifted?

In November 2025, Novavax completed the transfer of U.S. marketing authorization for its COVID-19 vaccine to Sanofi and reported third quarter results, which in...

Novavax Is Down 11.4% After Sanofi Vaccine Deal and Q3 Results - Has the Narrative Shifted?
Seeking Alpha 4d
Regeneron and Sanofi's Dupixent succeeds in late-stage study

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent (dupilumab) for treating allergic fu...

Regeneron and Sanofi's Dupixent succeeds in late-stage study

More SNY News

Nasdaq 4d
Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study

(RTTNews) - Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (...

Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3  Allergic Fungal Rhinosinusitis Study
TipRanks 4d
Regeneron, Sanofi announces presentation of Phase 3 trial of Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced the presentation of positive results from the pivotal LIBERTY-AFRS-AIMS Phase 3 trial evaluating the...

Nasdaq 4d
How The Parts Add Up: PID Targets $25

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average a...

How The Parts Add Up: PID Targets $25
TipRanks 7d
Novavax transfers U.S. marketing authorization for Nuvaxovid to Sanofi

Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.